Beleronap - Apurano Pharmaceuticals
Alternative Names: AP-703Latest Information Update: 11 Nov 2023
At a glance
- Originator Apurano Pharmaceuticals
- Class Behavioural disorder therapies; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Psychiatric disorders
Most Recent Events
- 16 Oct 2023 Preclinical trials in Psychiatric disorders in Germany (Sublingual), prior to October 2023 (Apurano Pharmaceuticals pipeline, October 2023)